Nitazoxanide against COVID-19 in three explorative scenarios

被引：23

作者：

Calderon, Jose Meneses ^{[1
,2
]}

Flores, Ma. del Rocio Figueroa

Coria, Leopoldo Paniagua ^{[1
]}

Garduno, Jesus Carlos Briones ^{[1
]}

Figueroa, Jazmin Meneses ^{[2
]}

Contreras, Maria Jose Vargas ^{[2
]}

Avila, Lilia de la Cruz ^{[1
]}

Meza, Salvador Diaz ^{[3
]}

Chacon, Reynaldo Ramirez ^{[4
]}

Padmanabhan, Srivatsan ^{[5
]}

Zeron, Hugo Mendieta ^{[1
,2
,6
]}

机构：

[1] Monica Pretelini Saenz Maternal Perinatal Hosp HM, Toluca, Mexico

[2] Autonomous Univ State Mexico UAEMex, Fac Med, Toluca, Mexico

[3] Dr Nicolas San Juan Gen Hosp, Toluca, Mexico

[4] Inst Seguridad Social Serv Trabajadores Estado IS, Mexico City, Tabasco, Mexico

[5] St Joseph Med Ctr, Tacoma, WA USA

[6] Cipres Grp Med CGM, Toluca, Mexico

来源：

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES | 2020年 / 14卷 / 09期

关键词：

Ambulatory treatment; internal medicine; nitazoxanide; pregnancy; SARS-CoV-2; INFECTIONS;

D O I：

10.3855/jidc.13274

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City. Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement. Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.

引用

页码：982 / 986

页数：5

共 23 条

[1] Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency [J].